Moreover, the levels of these compounds correlated significantly with clinical outcome, suggesting the possibility to further evaluate G-CSF and CXCL1 as therapeutic targets, therapeutics, or biomarkers in mastitis. The gene discussed is CSF3; the disease is mastitis.